A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease

Summary

The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease. It is a 6-month study enrolling 651 patients in Japan, Hong Kong, Korea, and Republic of China. All patients completing the 6-month study will be eligible to receive PF-01913539 in an open-label extension trial (B1451031).

Timeline

Start

2010-04

Primary completion

2012-03

Completion

2012-04

Drugs

Indications